https://journalajrid.com/index.php/AJRID/issue/feed Asian Journal of Research in Infectious Diseases 2021-09-23T02:33:24+00:00 Asian Journal of Research in Infectious Diseases contact@journalajrid.com Open Journal Systems <p style="text-align: justify;"><strong>Asian Journal of Research in Infectious Diseases (ISSN: 2582-3221)&nbsp;</strong>aims to publish&nbsp;high-quality&nbsp;papers (<a href="/index.php/AJRID/general-guideline-for-authors">Click here for Types of paper</a>) in all aspects of&nbsp;‘Infectious Diseases’. This journal facilitates the research and wishes to publish papers as long as they are technically correct, scientifically motivated. The journal also encourages the submission of useful reports of negative results. This is a quality controlled,&nbsp;OPEN&nbsp;peer-reviewed, open access INTERNATIONAL journal.</p> https://journalajrid.com/index.php/AJRID/article/view/30232 COVID-19 and Hypertension: A Mini-Review of Their Mutual Effect 2021-09-23T02:33:24+00:00 Udaya Ralapanawa udayapralapanawa@yahoo.com <p>Cases of Coronavirus disease are rapidly increasing across the world. Hypertension is the commonest co-morbidity among COVID-19 infected patients and hypertension is one of the determinants of severity of COVID-19.COVID -19 virus uses ACE-2 as an entry receptor and ACE-2 plays a vital role in blood pressure control in an individual. Certain antihypertensive medications may affect ACE-2 level and hence COVID-19 pathogenesis. At present, while the worlds focus is on the COVID-19, there is a danger that management of other illnesses like hypertension might be overlooked. It is highly recommended to take antihypertensive medications as directed and following healthy lifestyle practices like regular exercise, consuming low salt heart-healthy diet, maintaining a healthy weight and reducing stress, and practicing mindfulness even during this pandemic.</p> 2021-09-20T00:00:00+00:00 ##submission.copyrightStatement## https://journalajrid.com/index.php/AJRID/article/view/30230 Simulations of Infectious Disease Propagation II, Focusing on Herd Immunity 2021-09-20T03:02:15+00:00 William J. B. Oldham oldhamwj@yahoo.com <p><strong>Introduction and Objectives:</strong> The results of simulations of the propagation of an infectious disease are presented. In managing and controlling the spread of an infectious disease, such as Covid-19, the concept of Herd Immunity (HI) is often invoked as to when the disease’s propagation will dwindle to acceptable levels. We have extended a previous work with explicit attention on the usefulness of this concept. The objectives of this research was to track the propagation of an infectious disease as a function of population density, time, and to evaluate HI. The population was divided into two groups. One group was protected from the infection. The second group was unprotected. The results are given as a percentage of the unprotected population that is infected as a function of time.</p> <p><strong>Methods:</strong> The method used here was to use computer simulation on a person level to follow the progress of the diseases infection across the population. In the beginning, the people are uniformly distributed in a square. Each person performed a random walk, which simulated the movement of the people. Infection rates are given for the unprotected portion of the population as a function of time. The disease was transferred from an infected person to an uninfected person if the two people are closer together than a given distance.</p> <p><strong>Results and Discussion:</strong> These simulations show the unprotected portion of the population was at total risk if proper measures are not taken early. For 400 unprotected people the infection rate is 100% after approximately 100,000 iterations. We give the results from one dual simulation in which protection was afforded for a significant part of the population and carried out until all of the unprotected were infected. In the second part the protection was lifted to see how fast the total population was infected. For the case of 50% protected it took 400,000 iterations to infect the unprotected people. After the restrictions were lifted it took 150,000 to infect the other half. The simulations here were people based which has the advantage of seeing individual personal involvement. Results of infection rates were calculated for 1,000, 2,500, 5,000, and 10,000 people.</p> <p><strong>Conclusions:</strong> The propagation of the disease can be fast and depends on population density. Protection is vital to containing the disease. Restrictions must be lifted carefully and slowly or the total population is again at risk. According to the results obtained here the concept of HI is not a viable concept in controlling or managing the spread of the disease.</p> 2021-09-16T00:00:00+00:00 ##submission.copyrightStatement## https://journalajrid.com/index.php/AJRID/article/view/30231 Visceral Larva Migrans: A Rare Encounter by a Cytologist 2021-09-21T03:30:34+00:00 Neeti Nagar nagar.neeti27@gmail.com Neha K. Madan Richa Mittal Pradeep Kumar Debata Sunil Ranga <p>VLM is a zoonotic disease caused by the migration of third-stage larvae of nematodes through the tissue of human&nbsp;<a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/viscera">viscera</a>. Among various etiological agents such as&nbsp;<a href="https://www.sciencedirect.com/topics/medicine-and-dentistry/baylisascaris-procyonis">Baylisascaris procyonis</a>,&nbsp;Capillaria hepatica<em>,&nbsp;</em>Ascaris sum<em>, </em>and some<em>&nbsp;</em>Ancylostoma species<em>,&nbsp;</em>Toxocara&nbsp;is a major cause of VLM. Poor hygiene, contact with dogs and geophagia increases the risk of toxocariasis.Young adults and children who are in close contact with animals are at a higher risk. Here we present a case of 7 years male child presenting with fever, abdominal pain and vomiting. The clinical presentation, biochemical and radiological findings supported the diagnosis of VLM which was corroborated in the cytological examination. Here we report a rarest encounter of VLM in the cytology smear.</p> 2021-09-18T00:00:00+00:00 ##submission.copyrightStatement##